<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04310306</url>
  </required_header>
  <id_info>
    <org_study_id>4-2019-1057</org_study_id>
    <nct_id>NCT04310306</nct_id>
  </id_info>
  <brief_title>First-pass Recanalization With EmboTrap II in Acute Ischemic Stroke (FREE-AIS)</brief_title>
  <official_title>First-pass Recanalization With EmboTrap II in Acute Ischemic Stroke (FREE-AIS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a prospective, open-label, multi-center, registry study, designed to to
      documents that EmboTrap II usage as a thrombectomy device for emergency large vessel
      occlusion (ELVO) in terms of the rate of First Pass Recanalization (FPR). Patients with ELVO
      will initially underwent mechanical thrombectomy usig EmboTrap II. FPR is defined as modified
      Tissue Thrombolysis In Cerebral Ischemia (mTICI) 2b or 3
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 10, 2020</start_date>
  <completion_date type="Anticipated">December 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>3 Months</target_duration>
  <primary_outcome>
    <measure>First Pass Recanalization (FPR) rate</measure>
    <time_frame>Within 1 day after the completion of endovascular thrombectomyh</time_frame>
    <description>The rate of FPR defined by modified TICI 2b or 3</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The rate of modified Rankin scale 0-2 at 3 months after treatment</measure>
    <time_frame>90 days ± 14 days</time_frame>
    <description>The rate of modified Rankin Scale score (mRS), 0-2 at 90 days ± 14 days</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">310</enrollment>
  <condition>Acute Ischemic Stroke Due to Intracranial Large Artery Occlusion</condition>
  <arm_group>
    <arm_group_label>Rescue stenting group</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Thrombectomy using EmboTrap II</intervention_name>
    <description>The subjects will receive endovascular treatment for acute stroke according to standard clinical practice. Specifically, using a stent retriever, contact aspiration EmboTrap II. The number of thrombectomy attempts is at the operator's discretion. Combination of balloon guide catheter or intermediate catheter is recommended.</description>
    <arm_group_label>Rescue stenting group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with acute stroke due to ELVO within 24 hours after last seen well
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects experiencing acute ischemic stroke due to large vessel occlusion
             (intracranial internal carotid artery and middle cerebral artery M1 or proximal M2
             segment, intracranial vertebral artery and basilar artery

          2. Age 19 or greater

          3. mRS before qualifying stroke, 0 to 2

          4. Baseline NIHSS score 4 or more

          5. CT ASPECTS &gt; 5 or MR ASPECTS &gt; 4

          6. Good collateral statues on CT angiogram (collateral grade by Calgary group, 4 or 5) or
             corresponding to DEFUSE 3 or DAWN trial on perfusion imaging.

          7. Onset (last-seen-well) time to femoral puncture time &lt; 24 hours

          8. Anticipated life expectancy of at least 12 months

          9. Patients who undergo endovascular thrombectomy with EmboTrap II as the first-line
             device

         10. Signed informed consent for study enrollment

        Exclusion Criteria:

          1. Multiple simultaneous large vessel occlusions

          2. Pregnancy

          3. Severe contrast allergy or absolute contraindication to iodinated contrast agent

          4. Patient has a severe or fatal combined illness that will prevent improvement of
             follow-up or will render the procedure unlikely to benefit the patient.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Byung Moon Kim, PhD</last_name>
    <phone>82-2-2228-2399</phone>
    <email>bmoon21@yuhs.ac</email>
  </overall_contact>
  <location>
    <facility>
      <name>Severance Hospital Stroke Center, Yonsei University College of Medicine</name>
      <address>
        <city>Seongdu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Byung Moon Kim, PhD</last_name>
      <phone>82-2-2228-2399</phone>
      <email>bmoon21@yuhs.ac</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 13, 2020</study_first_submitted>
  <study_first_submitted_qc>March 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 17, 2020</study_first_posted>
  <last_update_submitted>March 13, 2020</last_update_submitted>
  <last_update_submitted_qc>March 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

